Determinants and prognostic implications of the negative diastolic pulmonary pressure gradient in patients with pulmonary hypertension due to left heart disease by Nagy, Anikó Ilona et al.
   
   1 
 
Determinants and prognostic implications of the negative diastolic pulmonary pressure 
gradient in patients with pulmonary hypertension due to left heart disease  
  
Anikó Ilona Nagy, MD, PhD* Ashwin Venkateshvaran, MSc#,**, Béla Merkely, MD, PhD*, Lars H. 
Lund, MD, PhD§,†, Aristomenis Manouras, MD, PhD§,†  
Affiliations: *Heart and Vascular Center, Semmelweis University, Budapest, Hungary #School for 
Technology and Health, Royal Institute of Technology, Stockholm, Sweden; **Sri Sathya Sai Institute 
of Higher Medical Sciences, Bangalore, India; §Department of Cardiology, Karolinska University 
Hospital, Stockholm, Sweden; †Department of Medicine, Karolinska Institutet, Stockholm, Sweden  
Corresponding author: 
Anikó Ilona Nagy, MD, PhD 
Semmelweis University, Heart and Vascular Center 
68. Városmajor utca, Budapest, H-1122, Hungary 
Telephone: +36208259738;  
E-mail: anychophora@gmail.com  
 
Running title: Nagy et al. Negative DPG in pulmonary hypertension  
Keywords: pre-capillary, post-capillary, V-wave 
   




Background. The diastolic pressure gradient (DPG) has recently been introduced as specific marker 
of combined pre-capillary pulmonary hypertension (Cpc-PH) in left heart disease (LHD). However, its 
diagnostic and prognostic superiority compared to traditional haemodynamic indices has been lately 
challenged. Current recommendations explicitly denote that in the normal heart, DPG values are 
greater than zero, with DPG ≥ 7 mmHg indicating Cpc-PH. However, clinicians are perplexed by the 
frequent observation of DPG < 0 mmHg (DPGNEG), as its physiologic explanation and clinical impact 
is unclear up-to-date.  
Aims. We hypothesized that large V-waves in the pulmonary artery wedge (PAWP) curve yielding 
asymmetric pressure transmission might stand for DPGNEG and undertook this study to clarify the 
physiological and prognostic implications of DPGNEG. 
Methods and results. Right heart catheterization and echocardiography was performed in 316 
patients with LHD due to primary myocardial dysfunction or valvular disease. 256 patients had PH-
LHD of whom 48% demonstrated DPGNEG. The V-wave amplitude inversely correlated with DPG 
(r=-0.45, p<0.001) in patients with low pulmonary vascular resistance, but not in those with elevated 
PVR (p>0.05). Patients with large V-waves had negative and lower DPG than those without 
augmented V-wave (p<0.001) despite similar PVR (p>0.05). Positive, but normal DPG (0-6 mmHg) 
carried a worse 2-year prognosis for death and/or heart transplantation than DPGNEG (HR: 2.97; 
p<0.05).  
Conclusion. Our results advocate against DPGNEG constituting a measurement error. We propose that 
DPGNEG can partially be ascribed to large V-waves and carries a better prognosis than DPG within the 
normal positive range.  
   




Pulmonary hypertension (PH) is a common complication of left heart disease (LHD). In isolated post-
capillary PH the pulmonary arterial pressure (PAP) elevation is governed solely by the upstream-
transmitted left atrial pressure (LAP). Long-standing post-capillary PH may however lead to 
pathological alterations of the pre-capillary vasculature, contributing to further PAP increase, a state 
denoted as combined post- and pre-capillary PH (Cpc-PH). Although this latter condition is clearly 
associated with worse prognosis 1,2, the optimal method to haemodynamically distinguish these two 
cohorts remains controversial.  
Traditionally, pulmonary vascular resistance (PVR) and transpulmonary gradient (TPG) have been 
employed for discerning Cpc-PH, both metrics bearing an established prognostic value in PH due to 
LHD (PH-LHD) 3,4. However, as both these markers are influenced by the LAP and stroke volume 5, 
their specificity has been questioned. In recent times, the diastolic pulmonary gradient (DPG), 
considered less affected by heart failure (HF) induced haemodynamic changes 5, has been introduced 
as a more reliable Cpc-PH index. Based on the above rationale and study results demonstrating 
prognostic superiority of the DPG 6,7, the Fifth World Symposium on PH proposed that a DPG ≥ 7 
mmHg alone should define Cpc-PH 5. However, the failure of two recent large-scale studies to 
confirm the prognostic value of DPG 8,9 raised concerns regarding its use in PH-LHD 8,10. Despite the 
significant prevalence of negative DPG values (DPGNEG), reportedly varying between 10- 50% 8,11, the 
physiological background and the potential prognostic implications of DPGNEG have yet not been 
investigated; rather, DPGNEG has arbitrarily been considered to represent measurement error 12. We 
hypothesized that prominent V-waves in the pulmonary artery wedge pressure (PAWP) recordings 
might stand for the DPGNEG by causing “asymmetrical” pressure transmission through the pulmonary 
capillaries i.e. a backward LAP wave reflection characterized by disproportionate phasic pressure 
changes. We therefore undertook the present study in order to 1, investigate the impact of V-waves on 
the DPG and particularly on the DPGNEG occurrence 2, elucidate the influence of PAWP as compared 
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to direct LAP measurements on the DPG and 3, assess the prognostic significance of DPGNEG 
compared to positive but normal DPG.  
 
METHODS 
Study population. The study population consisted of 316 patients in total. 192 patients were enrolled 
prospectively (86 consecutive patients with PH due to HF (denoted as PH-LHD in the following) 
referred for right heart catheterization (RHC) for HF assessment between January and December 2014 
were enrolled prospectively at Karolinska University Hospital, while 106 consecutive patients with 
severe rheumatic mitral valve stenosis (denoted as MS in the following) referred for percutaneous 
transvenous mitral commissurotomy (PTMC) between January and June 2012 were enrolled again 
prospectively at the Sri Sathya Sai Institute, Bangalore, India). In addition, 124 consecutive patients 
with PH-LHD referred for RHC at the Karolinska University Hospital were studied retrospectively. In 
all PH-LHD cases medical treatment had been titrated and haemodynamic stabilization achieved at the 
time of examination. None of the patients included in the study presented with acute coronary 
syndrome or had undergone cardiac surgery within 1 year before enrolment. In case of the MS cohort, 
subjects with > 1 grade mitral regurgitation, aortic valve disease, ischemic heart disease, atrial 
fibrillation (AF) or hypertension were not included in the study. In the PH-LHD cohort no specific 
exclusion criteria were applied, apart from patients with pressure tracings of inadequate quality (i.e. 
that would not have allowed reliable and reproducible identification of waveforms) were not included. 
A flowchart describing patient enrolment and haemodynamic grouping is provided in Figure S1. 
Follow-up data were collected form the Karolinska University Hospital database that is updated 
centrally; patients were followed until death, cardiac transplantation or the end of study period (mean 
time: 15.6 months). The prognostic value of DPGNEG vs. positive but normal DPG was assessed. The 
study was approved by the local ethics committee (registration number 2013/1991-32). All 
prospectively enrolled subjects provided written informed consent. All subjects underwent 
transthoracic echocardiography and RHC. 
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Catheterization. RHC was performed using a 6 F balloon-tipped fluid-filled Swan-Ganz catheter 
(Edwards Lifesciences, Irvine, California, USA) through the jugular or femoral vein access. Mean 
right atrial pressure (RAPM), diastolic (PAPD) and mean pulmonary artery pressure (PAPM), mean 
pulmonary artery wedge pressure (PAWPM) and right ventricular systolic pressure (RVSP) was 
recorded under fluoroscopy after calibration with the zero level set at the mid-thoracic line. All 
pressure tracings were stored in a connected haemodynamic recorder and analysed off-line with 
commercially available software (Xper Information Management, Philips Medical Systems, The 
Netherlands). Importantly, in order to ensure the uniformity of data acquisition and the standardization 
of the study the same investigator (AM) participated in RHC for all MS and the majority of PH-LHD 
patients and performed the analysis of all waveforms at both sites. From the PAWP recordings, the 
peak V- and A-wave and the PAWPM were obtained. All pressure measurements were averaged from 
a minimum of 5 heart cycles at end-expiration. Cardiac output (CO) was measured using Fick’s 
principle. The oxygen consumption was measured breath-by breath by dedicated gas analysis system. 
In 15 cases thermodilution was employed.  
PVR, TPG and DPG were calculated as: PVR= (PAPM-PAWPM)/CO; TPG=PAPM-PAWPM and 
DPG=PAPD-PAWPM, respectively. The difference between TPG and DPG (ΔPG), which equals 
PAPM-PAPD, was analysed in order to investigate diagnostic discrepancies by the two measures. Right 
ventricular stroke work index was calculated as RVSWi= (PAPM-RAPM)/SVi * 0.0136, where SVi 
denotes stroke volume index measured as: CO/HR/BSA. In MS patients measurements were 
performed prior PTMC. For full details of methods, please see the Supplementary material online. 
Simultaneous LAP and PAWP assessment: In 51 MS patients, simultaneous, beat-to-beat, LAP and 
PAWP tracings were obtained concurrently to right heart catheterization. Interatrial septal puncture 
was performed with an 8F Mullins’ sheath, dilator and a Brockenbrough needle. The LAP was 
measured directly through the Mullins' sheath used during valvuloplasty. Both transducers were 
zeroed after careful calibration, pressures were recorded during a 10 seconds period and stored for off-
line analysis.  
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Statistical analysis. The IBM SPSS statistics version 23.0 was used. Normality was tested by the 
Kolmogorov - Smirnov test. Continuous variables were expressed as mean ± SD or median and 
interquartile range. Categorical variables were expressed as absolute values and percentage. 
Comparisons of groups were performed with Mann-Whitney rank-sum test. Correlations were tested 
by the Pearson’s 2-tailed test. All tests were performed at 95% confidence intervals. A p-value of < 
0.05 was considered statistically significant. Receiver operator characteristics (ROC) was performed. 
Survival was analysed in the retrospectively studied 124 PH-LHD patients with Kaplan and Meier 
non-parametric test and compared using a log-rank test. Univariate and multiple Cox proportional 
hazards regression models were used to examine the effects of the DPG on patients’ survival. Age, 




Study Population. Of the 316 patients enrolled, 269 (84.5%) demonstrated PH (PAPM≥ 25 mmHg). 
Of these, 256 (95%, MS: 37%) had PH-LHD (PAPM≥ 25 and PAWPM>15mmHg). Demographics are 
presented in Table 1. Due to the different underlying pathology, the MS and PH-LHD groups were 
analysed separately. MS patients had higher PAPM, A- and V-waves and RVSWi compared to PH-
LHD group. However, DPG did not differ between the two groups (Table 2).  
V-wave influence on DPG. To evaluate the effect of the V-waves on the DPG we sub-grouped the 
cohort based on the presence of large V-waves, defined as the V-wave exceeding the PAWPM by the 
arbitrary limit of > 10 mmHg as previous investigators have performed 13. In the 69 cases (45%) with 
large V-waves (43 MS and 26 PH-LHD patients), the DPG was on average negative and lower (p< 
0.05) compared to those with smaller V-waves, despite similar levels of TPG, PVR, PAP and cardiac 
index (p> 0.05, for all comparisons, Table 3, Figure S2). 
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A significant inverse correlation between the V-wave and DPG was evident in patients with PVR <3 
WU (r= -0.45, p< 0.001), both in MS (r: - 0.34, p=0.03) and the PH-LHD group (r= - 0.46, p< 0.001). 
A weaker, yet statistically significant correlation (r=0.36; p=0.01) between the V-wave and DPG was 
found in patients with PVR 3-7 WU. However, this relation disappeared at higher PVR values (p> 
0.05; Figure 1A). Conversely, no association between the V-wave and TPG was observed (p> 0.05; 
Figure 1B). The modest overall correlation between the V-wave and DPG might be ascribed to the 
divergent association of the V-waves with PAPD at higher PAPM and PVR (Figure 1D), whereas the 
association between V-waves and PAWPM was essentially unaltered throughout the examined PAPM 
and PVR range (Figure 1C). 
Importantly, in patients with PVR< 3 WU, the V-wave showed the strongest correlation with the ΔPG 
(r=0.45, p< 0.001 for the whole cohort, r=0.36, p=0.005 for PH- LHD; r=0.6, p=0.003 for MS group, 
Figure 1E), with a weaker yet significant association of both the absolute and relative V-wave value 
with ΔPG (r= 0.26 and r=0.19, respectively; p< 0.05). Conversely, neither the A-wave nor the cardiac 
output correlated with ΔPG (p> 0.05, in all cases). 
The puzzling finding of normal DPG with concomitantly elevated TPG (>12 mmHg) is not unusual. 
Indeed, in our study 59 patients (23%, MS: 29%) TPG and DPG demonstrated incongruent 
diagnostics (TPG> 12, DPG< 7 mmHg). Furthermore, DPGNEG with concomitantly elevated TPG 
(>12 mmHg) occasionally occur. In our study we decided to quantify this discrepancy by calculating 
ΔPG (ΔPG=TPG-DPG). The ΔPG value that leads to discrepant Cpc-PH diagnostics between TPG and 
DPGNEG is 12 mmHg. In order to examine whether the V-wave amplitude impacted on this 
discrepancy we employed ROC analysis in patients with PVR< 3 WU. The association between ΔPG 
and V-wave amplitude is presented in Figure 1E. At an optimal cut-off limit of 30.5 mmHg, V-wave 
yielded a sensitivity of 85% and specificity of 70% (AUC: 0.80, CI: 0.72 to 0.88; p< 0.001) for the 
identification of ΔPG>12 mmHg (Figure S3). For the whole cohort of patients with PVR < 7 WU, the 
corresponding figures were: AUC 0.73, p<0.003; CI 0.61-0.84 at an optimal cut-off limit of V-wave 
of 31.5 mmHg). 
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In an attempt to investigate potential non-invasive and clinical determinants of the V-wave amplitude, 
LA-ESVi, LVMi, internal LV dimensions as well as the available clinical variables were tested. None 
of the tested variables, however, was associated with the V-wave (p>0.05 in all cases).  
Negative DPG values. In total, 123 patients (48%) demonstrated DPGNEG (median -3 mmHg; 
interquartile range: -5 to -2mmHg) with higher prevalence in the MS- compared to the PH-LHD group 
(55% vs. 44%, p< 0.05). MS patients had significantly higher V-waves (p< 0.001, Table 2). When the 
whole study population was considered, patients with DPGNEG showed significantly larger V-waves, 
lower PAPM, RAPM, PVR and TPG values whereas the PAWPM and cardiac index levels were 
comparable to those with positive DPG (Table 4). 
Assuming that pre-capillary changes differ between positive DPG and DPGNEG patients, we compared 
the two groups within a predefined PVR range (3 – 7 WU) in order to ensure comparatively 
equivalent degree of pre-capillary alterations between the two groups. Patients with DPGNEG 
demonstrated higher V-waves in both the MS and PH-LHD group, a less prominent right heart 
dilatation along with better RV function (p< 0.001) as compared to the positive DPG cohort, despite 
similar PAPM (p> 0.05, Table 4 and Table S1). Interestingly, the V-wave amplitude was similar in MS 
and PH-LHD patients in the DPGNEG group. 
 
Determinants of the DPG.   
1, LAP versus PAWP in DPG assessment. In the 51 MS patients with simultaneous PAWP and LAP 
recordings, the DPG was calculated from PAWP (DPGPAWP) and LAP (DPGLAP) separately. DPGPAWP 
was negative in 28 cases while DPGLAP in 22 cases due slightly yet not significantly lower (mean bias: 
- 2 mmHg) LAP (24.1 ± 8.0 mmHg) as compared to PAWP (26.0 ± 8.1 mmHg; p> 0.05). However, in 
only 3 cases with negative DPGPAWP the corresponding DPGLAP was positive, while in 1 case 
reclassification occurred in the opposite direction.  
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2, Heart rhythm. When the analysis was confined to the 192 patients with heart rate < 85 beats/min, 
52 % demonstrated DPGNEG. Similarly, when only the 53 patients in AF were considered, DPGNEG 
was measured in 50%.  
3, Alternative PAWP measurements. As detailed in Supplementary Results, when the DPG was 
calculated using PAWP value measured at the z-point of the PAWP curve, instead of using PAWPM in 
patients with DPGNEG, this resulted in significantly higher DPG values. Still, the prevalence of 
DPGNEG was not significantly reduced.  
 
Prognostic value of DPG. Two-year outcome for the combined end-point of death or cardiac 
transplantation was significantly better for PH-LHD patients with DPGNEG as compared to those with 
positive but normal DPG (0≤ DPG< 7 mmHg) (Figure 2A). In the DPGNEG group (n=57) the combined 
end-point was documented in 16 cases (10 deaths and 6 transplantations), while in the 0 ≤ DPG< 7 
mmHg group (n= 53) the corresponding figures were 24 (14 deaths and 10 transplantations). Finally, 
in the DPG≥ 7 mmHg group (n = 17) 8 combined end-point events were recorded (5 deaths and 3 
transplantations). 
The occurrence of the combined end-point of death or transplantation was significantly higher for 0≤ 
DPG< 7 mmHg both in unadjusted analysis (p< 0.005) and when adjusted for age, creatinine and 
ischemic heart disease (Figure 2B). Conversely, neither TPG (cut-off 12 mmHg) nor PVR (cut-off 3 
WU) provided significant prognostic information (p= 0.522 and p= 0.718, respectively). Furthermore, 
combining DPG and TPG [DPGNEG and TPG≤ 12 mmHg vs. 0≤ DPG< 7 and TPG>12 mmHg] also 
failed to provide prognostic information (p=0.223).  
 
DISCUSSION 
In the present study, we (1) confirm the high prevalence of DPGNEG in PH-LHD patients, (2) 
demonstrate that DPGNEG does not always represent measurement error, but instead may be ascribed 
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to high V-wave amplitude in patients with relatively low resistance in the pulmonary vascular bed, 
and (3) show that DPGNEG is associated with lower mortality as compared to the corresponding group 
of positive yet not elevated DPG.  
In healthy subjects and in patients without significant pre-capillary alterations, PAPD is closely related 
to the LAP, with DPG values ranging between 0-5 mmHg 5. DPGNEG have so far been regarded as 
measurement bias, ascribed to over-wedging or inaccurate PAPD recordings 5. However, the high 
DPGNEG prevalence, ranging from 20% in critically ill patients 11,14 to 35% 8 and up to 50% 15 in PH-
LHD patients calls for a reappraisal of its pathophysiologic origin. DPGNEG was found in 44% of our 
PH-LHD cohort, most probably reflecting the higher proportion of PH (95%) compared to that (45%) 
in a recent study 8.  
V-wave influence on DPG. During systole, the second phase of LA filling occurs, yielding the most 
prominent positive deflection of the PAWP waveform designated as the V-wave. The volume and the 
rate of blood entering the LA as well as this chamber’s compliance determine the V-wave’s amplitude 
16,17, which in healthy subjects averages at 12 mmHg, ranging between 4-19 mmHg, being at most 6 
mmHg higher than the LAPM 18. Importantly, the LA volume-pressure relation follows an exponential 
rather than a linear pattern, so that at lower LAP a certain volume entering the LA yields minor 
pressure elevation, whereas at higher LAP an equal inflowing volume results in a greater pressure  
rise 13,16. Conceivably, large V-waves arise not only in the presence of severe acute mitral 
regurgitation 19 but also in conditions such as MS 20 and longstanding LV dysfunction, when LA 
distensibility is impaired resulting in an upward shift of the LA volume-pressure curve. In our study, 
large V-waves were present in 20% of the PH-LHD group and in 46% of the MS cohort, similarly to 
the findings of Wang and colleagues 20. It should be emphasized that the augmented V-wave in these 
two cohorts represent distinct hemodynamic conditions; in MS it reflects increased LA stiffness due to 
obstructed mitral valve orifice, whereas in PH-LHD is mainly secondary to a rise in LV end-diastolic 
pressure. It has been shown that the distorted LAP waveform in the presence of large V-waves leads 
to overestimation of the LVEDP 21. Furthermore, there is evidence of retrograde superimposition of 
prominent V-waves on the PAP contour 22. Caro and colleagues demonstrated that at high LAP, the 
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ratio of pulmonary arterial to pulmonary venous compliance changes, promoting an asymmetrical 
backward transmission of the phasic LAP 23. Although, studies concomitantly reporting the V-wave 
amplitude and the PAPD are infrequent, the existing data on large V-waves in the context of increased 
LA stiffness reveal DPGNEG in essentially all cases 17. Importantly, we demonstrate that the inverse 
correlation between V-wave and DPG was confined to patients with relatively low PVR in accordance 
with the findings of Falicov and colleagues 15. Under physiological conditions, at end-diastole the 
pulmonary vascular bed allows pressure equilibration 24 which is otherwise hindered by the presence 
of vascular remodelling. Taken together, our results indicate that in PH-LHD the V-wave amplitude 
significantly influences the DPG calculation unless significant pre-capillary remodelling is present. 
However, with progressive maladaptive pre-capillary alterations the V-wave does not any more act as 
an important determinant of the DPG, which might be explained by increased stiffening of the 
pulmonary arteries and thus dampening of the backward LAP transmission. Previous investigations 
suggest that large V-waves inversely correlate to the ratio between the systolic and diastolic 
pulmonary inflow velocities 25. In accordance to previous investigators, LA-volume was not 
associated with the V-wave amplitude 26. As echocardiography plays a key role in the initial PH 
assessment in HF, further studies are warranted to address potential incremental value of this 
modality. 
Methodological considerations. The current findings argue against the notion that DPGNEG 
represents merely inaccurate measurement. Firstly, the PAWP and PAP waveforms were assessed 
manually at end-expiration by a single investigator, limiting the possibility of erroneous computerized 
PAPD measurements and preventing potential PAWPM underestimation due to pressure averaging 
throughout the respiratory cycle 27. Experimental studies have shown that heart rate (HR) impacts on 
DPG; at higher HR, DPG rises due to lower LVEDP and a concomitant PAPD  elevation 28. Our results 
reveal that even when confining the analysis to patients with normal HR or patients with AF, the 
incidence of DPGNEG was unaltered. Finally, our simultaneously performed PAWP and LAP 
measurements partly contradict the opinion that DPG would be a result of erroneous PAWP 
recordings. Direct LAP measurements yielded slightly higher DPG values as compared to PAWP. In 
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roughly 11% cases with negative DPGPAWP the corresponding DPGLAP was positive, while in 1 case 
reclassification occurred in the opposite direction (4.5%). This finding points to the fact, that due to its 
low absolute value, even a small measurement error will affect the DPG value, however, it also 
demonstrates, that measurement error stands only for a minority of DPGNEG cases. Taken together, 
although the slight discrepancy between LAP and PAWP might stand for a minor portion of the 
DPGNEG, our findings suggest that DPGNEG values can for the most part be ascribed to the augmented 
V waves. 
Prognostic significance. The prognostic impact of DPGNEG is as yet unknown. It has been suggested 
that patients with DPGNEG, instead of being a subclass of the isolated post-capillary PH (DPG<7 
mmHg) group, in fact represent a cohort with worse haemodynamics 8. Our findings contradict this 
hypothesis. We demonstrate that when comparing DPGNEG patients to those with 0≤ DPG< 7, within a 
predefined range of PVR (3-7 WU), the DPGNEG cohort is characterized by lower RAP, and higher 
TAPSE reflecting a state of less pronounced right heart loading and remodelling advocating for milder 
haemodynamic derangements in the DPGNEG group. This together with the lower event rate in the 
DPGNEG as compared to the DPG 0 – 7 mmHg cohort further supports the concept that DPGNEG in 
large part results from high V-waves shifting the DPG towards lower values, and suggests limited pre-
capillary changes.  
In our study, neither the PVR nor the TPG was associated with worse outcome. Furthermore, 
combining TPG and PVR with DPG failed to demonstrate significant prognostic value (p= 0.223 and 
p= 0.195, respectively). This observation stands in contrast to previous results and might be partly 
related to differences in patient profile. Indeed, as compared to the report by Tampakakis et al., the 
occurrence of ischemic heart disease was much higher in our study 8; additionally, our patient cohort 
comprised of older patients than that studied by Tampakakis et al. or Tedford et al. 8,9. Finally, the 
follow-up period was shorter in our study. The constellation of the aforementioned issues as well as 
the fact that our study comprised of fewer patients might stand for this discrepancy. 
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Limitations. Heterogeneity might be considered as comprising a limitation of the current study as 
catheterizations were performed in two different centres. However, all studies in India were performed 
in the presence of AM who was responsible for the standardization of the studies in the two centres; 
additionally the same technical equipment and catheters were used at both sites. Patient characteristics 
as well as haemodynamics of the two studied cohorts are also rather divergent, as demonstrated in 
Table 1 (e.g. patients with AF, hypertension or ischemic heart disease were excluded from the MS but 
not PH-LHD group), however as the objective of the present study was not to assess the influence of 
AF or other comorbidities on the DPG, but rather the effect of the V-wave amplitude on the DPG 
measurement, we believe that despite the patients’ heterogeneity, the hemodynamic essence of our 
hypothesis is still addressed. Our cohort comprised of patients with PH-LHD (including both 
preserved and reduced EF) and MS, in which respect it is different from previous comparable studies. 
Indeed, pre-capillary involvement as defined by DPG ≥ 7 mmHg was more frequent in MS patients 
(20.2%). However, the prevalence of Cpc-PH in the PH-LHD group was 13.6% that is comparable to 
previous studies (8-16%) 6,8,9. Finally, the current study was performed on hemodynamically stable 
patients implying that our findings might not be valid in a state of decompensated acute HF.  
 
CONCLUSION 
The present study verifies the recently observed high frequency of DPGNEG. We propose an applicable 
physiologic explanation for this haemodynamic finding demonstrating a significant inverse 
association of the V-wave amplitude in the PAWP waveform with the DPG in patients with low PVR. 
Using direct LAP measurements we show that the occurrence of DPGNEG is clearly not reflecting 
methodological inaccuracies; rather it largely represents the augmented disproportionate phasic LAP 
transmission. Finally, DPGNEG in patients with PH-LHD appears to be associated with milder 
haemodynamic derangements and better two-year prognosis compared to patients with DPG within 
the normal positive range.  
Additional Supporting Information may be found in the online version of this article.
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Figure 1 A, correlation between the diastolic pulmonary pressure gradient (DPG) and the V-wave 
amplitude in patients with low (PVR< 3 WU) and high (PVR ≥ 3 WU) pulmonary vascular resistance. 
B, correlation between the transpulmonary pressure gradient (TPG) and the V-wave amplitude in 
patients with low (PVR< 3 WU) and high (PVR ≥ 3 WU) PVR. C, Correlation between the mean 
pulmonary artery wedge pressure (PAWPM) and the V-wave amplitude in patients with low (PVR< 3 
WU) and high (PVR ≥ 3 WU) PVR. D, Correlation between the diastolic pulmonary artery pressure 
(PAPD) and the V-wave amplitude in patients with low (PVR< 3 WU) and high (PVR ≥ 3 WU) PVR. 
E, Correlation between the V-wave amplitude and ΔPG in patients with MS and PH-LHD. 
 
Figure 2A, Kaplan Meier analysis for the three diastolic pulmonary pressure gradient (DPG) groups. 
Group I, DPG < 0 mmHg; Group II, 0 ≥ DPG < 7 mmHg; Group III, DPG ≥ 7 mmHg. B, Hazard ratio 
for death and/or transplantation for patients with positive normal DPG (0 ≤ DPG < 7 mmHg) and 
negative DPG. Due to few patients in Group III, only the statistical comparison between Group I and 




Figure S1 Flowchart demonstrating the patient enrolment process and haemodynamic classification. 
MS, mitral valve stenosis; PH-LHD, pulmonary hypertension due to primary myocardial dysfunction; 
PTMC, percutaneous transvenous mitral commissurotomy; RHC, right heat catheterisation; HF, heart 
failure; MR, mitral regurgitation; IHD, ischaemic heart disease; AF, atrial fibrillation; HTN, systemic 
arterial hypertension, HTX, heart transplantation, PAPM, pulmonary artery mean pressure, PAWPM, 
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mean pulmonary artery wedge pressure; Cpc-PH, combined post- and pre-capillary pulmonary 
hypertension. 
 
Figure S2 Representative pressure tracings illustrating the influence of V-waves on the DPG value. A, 
PAWP waveform. B, PA waveform. DPG, diastolic pulmonary pressure gradient; TPG, 
transpulmonary gradient; PAWP, pulmonary artery wedge pressure; PAPD, pulmonary artery diastolic 
pressure  
 
Figure S3 Receiver operator characteristics (ROC) analysis of the prognostic ability of the V-wave 
(PAWPV) for identifying a ΔPG >12mmHg in patients with pulmonary vascular resistance (PVR) < 3 
Wood Units. ΔPG is defined as the difference between the transpulmonary pressure gradient (TPG) 
and the diastolic pulmonary pressure gradient (DPG).
   




Table 1: Demographic and echocardiographic data of the study population. 
 









      Demographics      
Age 50 ± 19 31 ± 9 61±15 <0.001 61±15 
Female (%) 51% 72% 39% <0.001 40% 
BSA (m2) 1.8 ± 0.3 1.4 ± 0.2 2.0 ± 0.2 <0.001 1.9± 0.2 




 0% 60%  45% 
Aetiology of HF      
     IHD (n, %)  0% 36 (22%)  32 (26%) 
     Idiopathic HF   68 (42%)  48 (39%) 
     Myocarditis   21 (13%)  6 (5%) 
 Other   37 (23%)  38 (31) 
AF (n, %) 53 (21%) 0 53 (33%)  43 (35%) 
Functional class      
NYHA II - IIIa  60 (64%) 84 (52%) <0.001 70 (56%) 
NYHA IIIb  34 (36%) 49 (30%) <0.001 29 (23%) 
NYHA IV  - 29 (18%)  25 (20%) 
Medication       
Diuretics  100% 81%  78% 
ACEi   85%  81% 
Beta Blockers  100% 98%  93% 
CCA   25%  18% 
MRA   31%  34% 
Echo data      
EF ≤45% 
 
69 (27%) 5 (5%) 62 (38%) <0.001 55 (44%) 
LVEDD (mm)  44 ± 7 52 ± 13 <0.001 54 ± 14 
LVESD (mm)  29 ± 0.4 41 ± 15 <0.001 43 ± 16 
LVMi (gr/m2)  64 ± 18 105 ± 50 <0.001 114 ± 55 
LA-ESVi (mL/m2)  68 ± 19 50 ± 21 <0.001 58 ± 20 
MVA (cm2)  0.8 ± 0.2    
MVG (mmHg)  19 ± 9    
RVEDD (mm)  36 ± 5 40 ± 8 <0.001 41 ± 7 
TAPSE (mm)  18 ± 3 14 ± 5 <0.001 14 ± 4 
MR grade      
     Mild 163 (63%) 64 (68%) 99 (61%) <0.001 82 (66%) 
     Moderate 23 (9%) - 23 (14%)  14 (11%) 
     Severe 17 (6%) - 17 (10.5%)  11 (9%) 
AS grade      
     Moderate 3 (1%) - 3 (2%)  4 (3%) 
AR (grade)      
    Mild 32 (13%) - 32 (20%)  31 (25%) 
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Data are expressed as expressed as mean ± SD. P values indicate the difference between the two 
prospective cohorts, i.e. MS and LHD. Abbreviations: SD, standard deviation; MS, mitral valve 
stenosis; PH-LHD, Pulmonary hypertension due to myocardial dysfunction; PH-LHD R, retrospective 
arm of the PH-LHD group; BSA, body surface area; HT, hypertension; DM, diabetes mellitus; IHD, 
ischemic heart disease; AF, atrial fibrillation; ACE-i, angiotensin converting enzyme inhibitors, β-
blockers, beta-blockers; CCA, calcium channel blockers; MRA, mineralocorticoid receptor antagonist, 
HR, heart rate; EF, ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, LV 
end-systolic diameter; LVMi, LV mass index; LA-ESVi, left atrial end-systolic volume index; MVA, 
mitral valve area; MVG, mitral valve mean diastolic gradient; RVEDD, right ventricular end-diastolic 
diameter; TAPSE, tricuspid annular positive systolic excursion; MR, mitral valve regurgitation; AS, 
aortic valve stenosis; AR, aortic valve regurgitation 
. 
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Table 2: Haemodynamics of the entire cohort. 






     
PAPM (mmHg) 35 (29 to 44) (256) 38 (30 to 50) (94) 34 (29 to 43) (162) 0.024 
PAPD (mmHg) 24 (20 to 31) (255) 27 (19 to 36) (94) 23 (20 to 29) (161) 0.026 
RVSP (mmHg) 24 (21 to 29) (256) 59 (47 to 83) (94) 40 (49 to 63) (162) <0.001 
PAWPM (mmHg) 24 (21 to 29) (256) 25 (23 to 32) (94) 23 (20 to 27) (162) 0.026 
A-wave (mmHg) 26 (22 to 32) (229) 31 (26 to 37) (91) 24 (21 to 28) (138) <0.001 
V-wave (mmHg) 31 (27 to 37) (235) 35 (31 to 44) (94) 28 (25 to 33) (141) <0.001 
CI (L/min/m2) 1.9 (1.6 to 2.4) (256) 1.7 (1.4 to 2.1) (94) 2 (1.7 to 2.5) (162) <0.001 
RAPM (mmHg) 10 (6 to 15) (255) 6 (3.8 to 8) (94) 12 (9 to 17) (161) <0.001 
RVSWi(g/m2/beat) 9 (6.6 to 13) (255) 10.4 (7.8 to 14.8) (94) 8.2 (6 to 12.2) (161) <0.001 
AV (mL/L) 54 (45 to 65) (241) 50 (42 to 57) (94) 57 (45 to 17) (147) <0.001 
DPG (mmHg) 0 (-3 to 4) (255) -1 (-4 to 5) (94) 0 (-3 to 3) (161) 0.327 
DPG < 7 -1 (-4 to 1) (83%) -2 (-5 to 0) (79%) -1 (-3 to 1) (85%)  
DPG ≥ 7 13 (9 to 15) (17%) 14 (10 to 18) (21%) 12 (9 to 14) (14%)  
TPG (mmHg) 10 (7 to 18) (256) 9 (6 to 21) (94) 11 (7 to 16) (162) 0.72 
TPG ≤ 12 8 (5.5 to 9) (61%) 7 (5 to 9) (62%) 8 (6 to 10) (61%)  
TPG > 12 20 (16 to 27) (39%) 25 (18 to 34) (38%) 19 (15 to 23) (39%)  
PVR (WU) 3 (1.8 to 5.2) (256) 4 (2.5 to 8.8) (94) 2.6 (1.7 to 4.5) (162) <0.001 
PVR < 3 1.8 (1.4 to 2.5) (51%) 1.9 (1.3 to 2.6) (36%) 1.8 (1. 3 to 2.4) (59%)  
PVR ≥ 3 5.3 (3.8 to 7.8) (49%) 7.1 (4.1 to 11.6) (64%) 4.8 (3.8 to 6.1) (41%)  
 
Abbreviations: MS, mitral stenosis; PH-LHD, pulmonary hypertension due to myocardial dysfunction; 
PAPM, PAPD , pulmonary artery mean and diastolic pressure, respectively; RVSP; Right ventricular systolic 
pressure; PAWPM, mean pulmonary artery wedge pressure; V- and A-wave, the maximal amplitude of the 
V- and A-wave of the PAWP waveform, respectively; CI, cardiac index; RAPM, mean right atrial pressure; 
RVSWi, right ventricular stroke work index; AV, arterio-venous difference of oxygen saturation; DPG, 
diastolic pulmonary pressure gradient; TPG, transpulmonary pressure gradient; PVR, pulmonary vascular 
resistance; WU, Wood Units. P value report the statistical difference between MS and LHD. Values are 
expressed in median and interquartile range. 
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Small V-wave signifies a difference between maximal amplitude of the V-wave of the PAWP 
waveform (PAWPv) and the mean pulmonary artery wedge pressure (PAWPM) i.e.  
V-waveabs of < 10 mmHg. Large V-wave signifies a V-waveabs ≥ 10 mmHg. MS, mitral stenosis; 
PAPM and PAPD, pulmonary artery mean and diastolic pressure respectively; PAWPM, mean 
pulmonary artery wedge pressure; PVR, pulmonary vascular resistance; TPG, transpulmonary 
pressure gradient; DPG, diastolic pulmonary pressure gradient; CI, cardiac index; WU, Wood Units; 
Values are expressed in median and interquartile range. 
 Small V-waves 
n=166 (51 MS) 
Large V-waves 
n=69 (43 MS) 
p 
    PAPM (mmHg) 34 (29 to 44) 35 (30 to 45) 0.36 
PAPD (mmHg) 24 (20 to 30) 23 (19 to 32) 0.77 
PAWPM (mm Hg) 23 (20 to 27) 25 (22 to 31) 0.001 
V-wave (mmHg) 28 (25 to 32) 39 (34 to 46) < 0.001 
V-waveabs (mmHg) 5 (3 to 7) 13 (11 to 17) < 0.001 
PVR (WU) 2.9 (1.9 to 5.6) 3.1 (1.7 to 5.2) 0.73 
TPG (mmHg) 11 (7 to 19) 9 (7 to 15) 0.39 
DPG (mmHg) 0 (-2 to 5) -2 (-4 to 1) 0.002 
CI (L/min/m2) 1.9 (1.6 to 2.4) 1.8 (1.6 to 2.5) 0.26 
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Table 4. Comparison of negative and positive DPG groups within the entire study population 
and in patients with a predefined PVR range of 3 - 7 WU. 
 
 
All patients PVR 3 -7 WU 
DPG < 0 
 
DPG ≥ 0 
 
DPG < 0 
 
DPG ≥ 0 
 (n) (n) (n) (n) 
     
MS patients (n) 52 (42 %) 42 (32 %) 18 (64 %) 11 (19 %) 
PAPM (mmHg) 31 (28 to 37) (123) 41 (33 to 49) (132) 
(p<0.001) 
38 (30 to 43) (28) 40 (34 to 45) (57) 
(p=0.128) 
PAPD (mmHg) 20 (17 to 26) (123) 28 (23 to 35) (132) (p<0.001) 
23 (18 to 30) (28) 27 (24 to 31) (57) 
(p=0.013) 
V-wave (mmHg) 33 (28 to 39) (112) 29 (25 to 36) (123) 
(p<0.001) 
37 (32 to 42) (26) 28 (24 to 33) (52) 
(p<0.001) 
PAWPM (mmHg) 24 (21 to 29) (123) 24 (20 to 28) (132) (p=0.06) 
25 (21 to 32) (28) 24 (20 to 28) (57) 
(p=0.071) 
RVSP (mmHg) 49 (41 to 59) (123) 62 (47 to 78) (132) 
(p<0.001) 
51 (46 to 32) (28) 61(47 to 71) (56) 
(p=0.67) 
RAPM (mmHg) 9 (5 to 13.5) (123) 11 (7 to 15) (132) 
(p=0.004) 
7.5 (4 to 10) (28) 11 (7 to 15) (57) 
(p=0.005) 
PVR (WU) 2.2 (1.4 to 3.0) (123) 4.7 (2.6 to 7.6) (132) 
(p<0.001) 
4 (3.4 to 4.8) (28) 4.7 (3.7 to 5.6) (57) 
(p=0.09) 
DPG (mmHg) -3 (-5 to -2) (123) 3 (1 to 9) (132) 
(p<0.001) 
-2.5 (-4 to -1) (28) 3.0 (1 to 5) (57) 
(p<0.001) 
TPG (mmHg) 7 (5 to 9) (123) 16 (11 to 24) (132) 
(p<0.001) 
9 (8 to 14) (28) 15 (12 to 21) (57) 
(p<0.001) 
CI (L/min/m2) 1.9 (1.6 to 2.5) (123) 1.9 (1.6 to 2.3) (132) 
(p=0.392) 
1.7 (1.3 to 1.9) (28) 1.8 (1.6 to 2.2) (57) 
(p=0.034) 
RVSWi (gr/m2/beat) 8.2 (6.4 to 11) (123) 10.5 (6.8 to 15) 
(p=0.004) 
8.4 (6 to 12.6) (28) 10.3 (6.3 to 14) (57) 
(p=0.24) 
A-V (mL/L) 49 (42 to 59) (115) 58 (48 to 69 (126) 
(p<0.001) 
49 (41 to 63) (28) 62 (49 to 71) (53) 
(p=0.04) 
TAPSE (mm) 17 (12 to 19) (123) 15 (12 to 18) (132) 
(p=0.025) 
18 (15 to 21) (28) 14 (11 to 17) (57) 
(p=0.004) 
RA area (cm2) 18 (12 to 24) (123) 22 (15 to 27) (132) 
(p=0.002) 
12 (10 to 24) (28) 23 (18 to 29) (57) 
(p<0.001) 
RVEDD (mm) 36 (33 to 41) (123) 38 (34 to 46) (132) 
(p<0.003) 
34 (33 to 43) (28) 40 (36 to 48) (57) 
(p=0.005) 
 
MS, mitral stenosis; PAPM and PAPD pulmonary artery mean and diastolic pressure respectively; 
PAWPM and V-wave, mean pulmonary artery wedge pressure and the maximal amplitude of the V-
wave of the PAWP waveform, respectively; RVSP; right ventricular systolic pressure; RAPM, right 
atrial mean pressure; PVR, pulmonary vascular resistance; TPG, transpulmonary pressure gradient; 
DPG, pulmonary diastolic pressure gradient; CI, cardiac index; RVSWi, right ventricular stroke work 
index; A-V, arterio-venous difference in oxygen saturation; TAPSE, tricuspid annular plane systolic 
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excursion; RA, right atrium; RVEDD, right ventricular end-diastolic diameter; WU, Wood Units; 
Values are expressed in median and interquartile range. 
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Table S1. Comparison of negative and positive DPG groups in MS and LHD patients with a 
predefined PVR range of 3 - 7 WU. 
 PH-LHD  MS  
     DPG < 0 
(n=10) 
DPG ≥ 0 
(n=46) p 
DPG < 0 
(n=18) 
DPG ≥ 0 
(n=11) 
p 
PAPM (mmHg) 40.5 (31.3 to 45.5) 43 (34 to 45) 0.223 33.5 (29.8 to 43.5) 36 (33 to 38) † 0.152 
PAPD (mmHg) 21.5 (18.3 to 28.8) 27 (24 to 31) 0.03 22.5 (18.5 to 30.3) 26 (24 to 31) 0.112 
V-wave (mmHg) 37 (31.5 to 39.8) 27 (24 to 32) 0.002 37 (32 to 45) 33 (28 to 39) † 0.02 
A-wave (mmHg) 26 (16 to 28) 24 (21 to 28) 0.185 30.5 (26.5 to 37.5)† 28.5 (22 to 35) 0.123 
PAWPM (mmHg) 24 (21.3 to 31.3)
 22 (19 to 29) 0.181 25 (21 to 32.5) 24 (23 to 30) 0.176 
PVR (WU) 3.9 (3.2 to 4.5) 4.8 (3.8 to 5.7) 0.04 4.1 (3.5 to 5.1) 4.2 (3.5 to 5.7) 0.154 
DPG (mmHg) -2.5 (-3 to -1) 3.0 (1 to 7) < 0.001 -2.0 (-4 to -1) 2 (0 to 3) † <0.001 
TPG (mmHg) 13.5 (9 to 17.8) 21 (18 to 27) 0.005 9 (7.8 to 11) † 11 (9 to 12) † 0.110 
 
PH-LHD, pulmonary hypertension due to myocardial dysfunction; MS, mitral stenosis; PAPM and 
PAPD pulmonary artery mean and diastolic pressure respectively; PAWPM and V-wave, mean 
pulmonary artery wedge pressure and the maximal amplitude of the V-wave of the PAWP waveform, 
respectively; PVR, pulmonary vascular resistance; TPG, transpulmonary pressure gradient; DPG, 
pulmonary diastolic pressure gradient. Values are expressed in median and interquartile range; † 
denotes significant difference between MS and PH-LHD group. 
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DPGPAWPM -3.6 2.63 -3.0 -5 to -1 0.014 
DPGz-point -2.35 2.38 -2.2 -4 to - 0.6  
 
B 









      
DPGPAWPM -4.1 2.6 -4.0 -6.5 to -2 0.02 
DPGz-point -1.9 2.7 -1.0 -4 to -0.5  
 
A, 34 PH-LHD patients with DPGNEG. B, Subgroup of the previous 34 patients with large V-waves (16 
individuals). DPG, diastolic pressure gradient; DPGPAWPM, DPG calculated using PAWPmean; DPGz-
point, DPG calculated using z-point of the PAWP curve; SD, standard deviation. 
 
 
